Shareholder Update

Current status update

Please bookmark this page and check back periodically for the latest updates on news, events, and milestone achievements of interest to shareholders and investors.

Presentation at the August 22, 2013 Annual Meeting of Shareholders

Stan Myrum reviews our progress and outlines future plans (Presentation).

July, 2013 Letter To Shareholders Included In The Proxy Mailing.

In this Letter To Shareholders Stan Myrum outlines our progress over the last year and makes observations about developments in the marketplace.

A Message to Shareholders from Interim CEO Stan Myrum

In this letter to shareholders, Stan outlines ProUroCare’s future plans [posted May 1, 2013].

ProUroCare Announces Changes to Management and Board of Directors

ProUroCare Medical Inc. is pleased to announce the appointment of Stan Myrum as Interim CEO of the company and as a Director on its Board of Directors.  Stan has over 30 years of medical device experience with Medtronic where he provided executive leadership in Operations, Supply Chain, Quality, Regulatory, Clinical and Product Development.Rick Carlson, the prior CEO of ProUroCare, will transition to a new role as a consultant for Marketing and Physician Relations.  This transition is consistent with Rick’s expertise in these two very important areas for the company.  In the near term the company will focus on scaling back expenses while completing the multiple use probe approval process.  The company’s CFO, Dick Thon, will continue as an employee for a short time and then convert to a financial consulting role.  Dr. Michael Chambers and Larry Getlin, Directors, have resigned from the ProUroCare Board, but will continue to serve in their areas of expertise as consultants.  The Board is now comprised of Jim Davis (CEO of Davis Associates), Robert Rudelius (CEO of Nobles Ventures) Scott Smith (Managing Director of Accretive Solutions), and Stan Myrum, all based in Minneapolis or working there regularly.   Dr. Chambers stated, “This structure will center and accelerate all decision-making during this period into a small group of people, centrally located and at a reduced cost to the company.” Full Press Release.

ProUroCare Medical Submits Cleaning and Disinfection Protocol to FDA

ProUroCare Medical Inc. has submitted a Cleaning and Disinfection Protocol for its ProUroScan(TM) prostate mechanical imaging system to the U.S. Food & Drug Administration (FDA). The submission requests that the FDA review the cleaning and disinfection validation protocol for the ProUroScan’s sensor probe prior to initiating testing and preparation of a final test report. The results of this study will be incorporated in the multi-use labeling claim that the company will pursue in a subsequent 501(k) filing.  Full Press Release.